Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Zealand Pharma
  4. Zealand Pharma — Juni 2023

Zealand Pharma — Juni 2023

Planlagt Fastgjort Låst Flyttet Zealand Pharma
559 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    Pensionisten
    wrote on sidst redigeret af
    #219

    Det er vel netop ideen - sælg på ATH, og køb igen når under.

    1 Reply Last reply
    0
    • Y Offline
      Y Offline
      YPE
      wrote on sidst redigeret af
      #220

      Ved I, om man kan se/høre konferencen i aften?

      1 Reply Last reply
      0
      • E Offline
        E Offline
        EliotSpitzer
        wrote on sidst redigeret af
        #221

        Jeg er ret sikker på at du skal betale et deltaker-
        gebyr for at høre præsentationen, Men jeg regner med at der kommer en pressemeddelse ud om tal og evt.,annonsering af fase 3.

        1 Reply Last reply
        0
        • SvingtraderenS Offline
          SvingtraderenS Offline
          Svingtraderen
          wrote on sidst redigeret af
          #222

          vi må godt nok vente i spænding

          1 Reply Last reply
          0
          • Y Offline
            Y Offline
            YPE
            wrote on sidst redigeret af
            #223

            I lyder meget sikre. Er der egentlig lagt op til de gode nyheder eller? Jeg holder øje med indbakken

            1 Reply Last reply
            0
            • A Offline
              A Offline
              Aps_invest
              wrote on sidst redigeret af
              #224

              Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)1

              1 Reply Last reply
              0
              • A Offline
                A Offline
                Aps_invest
                wrote on sidst redigeret af
                #225

                Blocked

                Short description

                favicon

                (www.zealandpharma.com)

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  EliotSpitzer
                  wrote on sidst redigeret af
                  #226

                  Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    EliotSpitzer
                    wrote on sidst redigeret af
                    #227

                    Det her super resultater!

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      EliotSpitzer
                      wrote on sidst redigeret af
                      #228

                      Hvis de kan bringe tallene høyere i fase 3 på grund af bedre titering af dosis kan den blive «best in class» men det er spekulation frem til nu.

                      1 Reply Last reply
                      0
                      • M Offline
                        M Offline
                        Milito
                        wrote on sidst redigeret af
                        #229

                        Vildt

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          Goose3
                          wrote on sidst redigeret af
                          #230

                          Så passede rygterne i midtugen. Vildt nok.

                          1 Reply Last reply
                          0
                          • M Offline
                            M Offline
                            Milito
                            wrote on sidst redigeret af
                            #231

                            Fantastisk nyt

                            1 Reply Last reply
                            0
                            • M Offline
                              M Offline
                              Milito
                              wrote on sidst redigeret af
                              #232

                              Ja gad vide hvor de 18,7% kom fra

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                EliotSpitzer
                                wrote on sidst redigeret af
                                #233

                                Her er nyhed fra Reuter, hvor der også er citater fra lidt interview. https://www.reuters.com/business/healthcare-pharmaceuticals/zealand-boehringer-tout-higher-weight-loss-drug-efficacy-update-2023-06-23/

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  EliotSpitzer
                                  wrote on sidst redigeret af
                                  #234

                                  The partners are also eyeing better efficacy by running the planned Phase III trial for longer because weight loss was not yet levelling off at the Phase II study's 46 week cut-off time.

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    EliotSpitzer
                                    wrote on sidst redigeret af
                                    #235

                                    Det betyder at et længere studie kan bringe effekt tallene op. Men det skal dog oså nævnes at en del fald fra på bivirkninger.

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      EliotSpitzer
                                      wrote on sidst redigeret af
                                      #236

                                      The design of the Phase III trial is being discussed with regulators, said Boehringer's Casarosa. She would not be drawn on when to expect results. = Vi må fortsat vente på annoncering af fase III

                                      1 Reply Last reply
                                      0
                                      • L Offline
                                        L Offline
                                        lassevedel96
                                        wrote on sidst redigeret af
                                        #237

                                        24.6% discontinuation pga. adverse events er godt nok højt. Håber de kan bringe det ned med bedre titrering

                                        1 Reply Last reply
                                        0
                                        • H Offline
                                          H Offline
                                          hanfrank12
                                          wrote on sidst redigeret af
                                          #238

                                          Godmorgen, - Eliot, tænker du ikke, der i det mindste er tale om en "lille annoncering", når man nu vil diskutere designet?! Mht. frafald pga. bivirkninger, så gætter jeg da på, at man, business as usual, givetvis tager god højde for dette i patientudvælgelsen til fase 3 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper